26178
document
Eberconazole 1 % cream is an effective and safe alternative for dermatophytosis treatment : multicenter , randomized , double-blind , comparative trial with miconazole 2 % cream . BACKGROUND Eberconazole is a topical , broad-spectrum imidazole derivative , effective in dermatophytoses , candidiasis , and pityriasis treatment . In previous trials , it showed a higher efficacy than clotrimazole in the treatment of dermatophytoses . The purpose of this trial was to evaluate the efficacy of eberconazole 1 % cream compared with miconazole 2 % cream in the treatment of dermatophytoses . METHODS A multicenter , double-blind , randomized trial was performed in 653 patients with dermatophytoses , randomized to eberconazole 1 % cream every 12 h or miconazole 2 % cream every 12 h for 4 weeks . Treatment efficacy was assessed on the basis of the percentage of effective response after 4 weeks through mycologic and clinical assessment . RESULTS Of the 653 patients included in the trial , 360 produced positive baseline mycologic cultures and were included in the efficacy assessment . Clinical efficacy was shown in 76.1 % of patients receiving eberconazole and in 75.0 % of patients receiving miconazole . The incidence of adverse events related to treatment was 0.91 % for eberconazole and 0.92 % for miconazole , none being serious , and all being local and transient . CONCLUSIONS Eberconazole 1 % cream is an effective treatment for fungal infections produced by dermatophytes , with a good safety and tolerability profile , and can be considered a good alternative for the treatment of dermatophytoses .
26179
Intervention_Pharmacological
Eberconazole
26180
Intervention_Pharmacological
miconazole
26181
Intervention_Pharmacological
Eberconazole
26182
Intervention_Pharmacological
eberconazole
26183
Intervention_Pharmacological
miconazole
26184
Intervention_Pharmacological
eberconazole
26185
Intervention_Pharmacological
miconazole
26186
Outcome_Other
effective and safe
26187
Outcome_Other
Treatment efficacy
26188
Outcome_Adverse-effects
adverse events
26189
Outcome_Other
safety and tolerability